Aluf CBD Partners LLC
A wholly owned subsidiary of Aluf Holdings, Inc.
We invest in the manufacturing and processing of CBD distillate in order to fulfill the growing client need in the CBD marketplace.
Profitability. With the passing of the U.S. Farm bill in December 2018, making hemp-derived CBD legal, is creating enormous market demands for its products. The U.S. Cannabis market, including hemp-based derivatives and CBD, is projected to expand from $10 billion to $75 billion by 2030. The potential market opportunity for CBD is expected to reach $16 billion in the next five years with hemp-based derivatives reaching $3 billion by the year 2020.
What is CBD?
CBD stands for cannabidiol. It is derived directly from the hemp plant, which is a cousin of the marijuana plant. It is a naturally occurring compound found in the resinous flower of cannabis, a plant known and used for its medicinal properties going back thousands of years. Today the therapeutic properties of CBD are being tested and confirmed by scientists and doctors around the world as a safe, non-addictive substance.
What is CBD Distillate?
The production of distillate begins with crude extraction* using state-of-the-art extraction processes known as distillation. Distillate, a clear golden viscous liquid, is one of the purest and most potent forms of cannabinoids. It is used in a variety of products such as supplements, topical creams, skincare, and even pet care.
What is CBD Isolate?
CBD isolate, a tasteless, odorless, fine white powder, is CBD in its purest form – it is isolated cannabidiol. During the extraction process, everything is removed or filtered out except the CBD. CBD isolate may be used as a dietary supplement for a wide range of health benefits including migraines, PTSD, pain, and many others.
What is Crude?
Crude oils are extracted and mixed with a vegetable oil but undergo no further processing.
“The number one goal of Aluf is to build shareholder value through profitability. Although this initiative is outside the scope of our primary focus on “technology,” the U.S. Cannabis market, including hemp-based derivatives and CBD, is projected to expand from $10 billion to $75 billion by 2030. Conservatively speaking, we are projecting average “blended” gross profits in excess of $18.5 million annually over the next five years.“
– Teresa McWilliams, Aluf Holdings, Inc. CFO & Interim President/CEO.
We do not manufacture or sell any CBD products to the general public.
For more information contact: InvestorRelations@Aluf.com